TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03346720

Intervention type: OTHER
Intervention: Semi-structured interviews
Description: These interviews will be conducted following an interview guide. Interviews will be conducted in English or Thai at a place convenient and familiar to the interviewee. It is estimated that each interview will last between 45 minutes to an hour.

Intervention type: OTHER
Intervention: Semi-structured interviews
Description: These interviews will be conducted following an interview guide. Interviews will be conducted in English or Thai at a place convenient and familiar to the interviewee. It is estimated that each interview will last between 45 minutes to an hour.

Intervention type: OTHER
Intervention: Semi-structured interviews
Description: These interviews will be conducted following an interview guide. Interviews will be conducted in English or Thai at a place convenient and familiar to the interviewee. It is estimated that each interview will last between 45 minutes to an hour.

Intervention type: OTHER
Intervention: Semi-structured interviews
Description: These interviews will be conducted following an interview guide. Interviews will be conducted in English or Thai at a place convenient and familiar to the interviewee. It is estimated that each interview will last between 45 minutes to an hour.

Intervention type: OTHER
Intervention: Focus group discussions (FGDs)
Description: These will be conducted following an interview guide. FGDs will be conducted in English or Thai. In addition, a note taker will be present to take notes. FGDs will take place at a place convenient and familiar to the participants. It is estimated that each FGD will last between 1 to 1.5 hours. FGDs will typically consist of homogenous groups e.g. study nurses.

Intervention type: OTHER
Intervention: Focus group discussions (FGDs)
Description: These will be conducted following an interview guide. FGDs will be conducted in English or Thai. In addition, a note taker will be present to take notes. FGDs will take place at a place convenient and familiar to the participants. It is estimated that each FGD will last between 1 to 1.5 hours. FGDs will typically consist of homogenous groups e.g. study nurses.

Intervention type: OTHER
Intervention: Focus group discussions (FGDs)
Description: These will be conducted following an interview guide. FGDs will be conducted in English or Thai. In addition, a note taker will be present to take notes. FGDs will take place at a place convenient and familiar to the participants. It is estimated that each FGD will last between 1 to 1.5 hours. FGDs will typically consist of homogenous groups e.g. study nurses.

Intervention type: OTHER
Intervention: Focus group discussions (FGDs)
Description: These will be conducted following an interview guide. FGDs will be conducted in English or Thai. In addition, a note taker will be present to take notes. FGDs will take place at a place convenient and familiar to the participants. It is estimated that each FGD will last between 1 to 1.5 hours. FGDs will typically consist of homogenous groups e.g. study nurses.
Study: NCT00260143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04290351

Intervention type: PROCEDURE
Intervention: band ligation
Description: Rubber band ligation will be applied to patients, and then phlebotonic will be prescribed.~(Note: The researcher has no contribution or intervention to the treatment method. Patients receiving this treatment will be observed.)

Intervention type: DRUG
Intervention: oral 450 mg diosmin+50 mg hesperidin
Description: 450 mg diosmin + 50 mg hesperidin will be prescribed to patients undergoing band ligation.~(Note: The researcher has no contribution or intervention to the treatment method. Patients receiving this treatment will be observed.)

Intervention type: DRUG
Intervention: oral 450 mg diosmin+50 mg hesperidin
Description: 450 mg diosmin + 50 mg hesperidin will be prescribed to patients undergoing band ligation.~(Note: The researcher has no contribution or intervention to the treatment method. Patients receiving this treatment will be observed.)
Study: NCT00464646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Both Cohorts: Epirubicin 90 mg/m2 IV every 21 days x 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Both Cohorts: Cyclophosphamide 600 mg/m2 IV every 21 days x 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Both Cohorts: Docetaxel 100 mg/m2 IV on Day 1 every 21 days x 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Cohort A: Pre-op therapy - 4 mg/kg IV first dose, then subsequent doses at 2 mg/kg IV weekly (16+ weeks) until 1-7 days prior to surgery. Post-operative therapy (beginning no sooner than 28 days after surgery and continuing every 3 weeks x 13 doses) - 8 mg/kg IV first post-op dose, then subsequent doses at 6 mg/kg IV~Cohort B: 4 mg/kg IV first dose, then subsequent doses at 2 mg/kg IV weekly on days 1, 8, and 15. Three (3) weeks after last dose of docetaxel, 6 mg/kg IV and continuing every 3 weeks x 13 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Cohort A: Cycles 1-4, 15 mg/kg IV on day 1 of cycle 4 only; Cycles 5-7, 15 mg/kg IV on day 1 every 21 days x 3 cycles; post-operative therapy (beginning no sooner than 28 days after surgery), 15 mg/kg IV every 3 weeks x 13 doses~Cohort B: Cycles 5-8, 15 mg/kg IV on day 1 every 21 days x 4 cycles; beginning 3 weeks after last dose of docetaxel, 15 mg/kg IV every 3 weeks x 13 doses
Study: NCT04050241

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glidescope intubation
Description: Anesthetists will perform intubation in patients undergoing elective neurosurgery with the Glidescope videolaryngoscope, while completing a secondary auditory task. Response times to the secondary task will be recorded, and operators will complete the NASA Task Load Index questionnaire at the end of each procedure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mcintosh intubation
Description: Anesthetists will perform intubation in patients undergoing elective neurosurgery with the Mcintosh laryngoscope, while completing a secondary auditory task. Response times to the secondary task will be recorded, and operators will complete the NASA Task Load Index questionnaire at the end of each procedure.
Study: NCT00192309

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAIV-T
Description: Liquid CAIV-T vaccine for this study consisted of three cold-adapted, attenuated, reassortant strains representing the hemagglutinin (HA) and neuraminidase (NA) antigens of the A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2) and B/Yamanashi/166/98 influenza virus strains. The reassortant vaccine strains were grown in specific pathogen-free (SPF) eggs and the allantoic fluid, which contained virus, was harvested, concentrated and purified. Each dose of CAIV-T used in this study was formulated to contain approximately 107 FFU of each of the 6:2 influenza reassortant vaccine strains.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TIV
Description: TIV in this study consisted of Flushield™, manufactured by Wyeth Vaccines, Marietta, PA, USA. Each 0.5 mL dose contained no less than 15 ug of the hemagglutinin antigens from each of the A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2), and B/Yamanashi/166/98 strains, making TIV in this study antigenically matched to the influenza strains contained in CAIV-T.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in this study consisted of physiological saline. The total volume of 0.2 mL was administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).
Study: NCT01083654

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment Counseling
Description: Standard Treatment Counseling will be based on recommendations in the 2008 U.S. Public Health Service Guideline (Treating Use and Dependence) including topics on preparing to quit, nicotine addiction, coping with stressors and challenging situations, coping with withdrawal symptoms, seeking support, and relapse prevention. Counseling will be delivered in an accessible, personalized manner by Ms. Fossum (an enrolled member of the Menominee Tribe) but no American Indian culturally-appropriate treatment elements will be incorporated into the counseling. In other words, the counseling in the Standard Treatment will be similar to the kind of evidence-based counseling offered to other smokers regardless of race or ethnicity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally-Tailored Treatment
Description: The Culturally-Tailored Treatment consists of the Standard Treatment Counseling plus culturally-appropriate treatment elements including: discussion of the long history of sacred/traditional use of tobacco (honoring and respecting native traditions) and how it differs from use of commercial tobacco use (harming health); custom booklet on smoking and smoking cessation tailored for Menominee and other American Indian smokers; and participants will be encouraged to make their own traditional tobacco pouch (symbol of long life)
Study: NCT01972438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASEDs
Description: Experimental Intervention

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ASEDs
Description: Experimental Intervention
Study: NCT02608866

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SF-SSRS
Description: Spine stereotactic radiosurgery/ablative radiotherapy (SSRS) with 16 Gy in single fraction to the defined target volume using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MF-SSRS
Description: SSRS with 24 Gy in three fractions to the defined target volume using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc). Treatment should be given on every other day. Treatment on the consecutive days to the same target volume is not allowed.
Study: NCT04493931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gepotidacin
Description: Gepotidacin tablets will be available as unit dose strength 750 mg and will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gepotidacin
Description: Gepotidacin tablets will be available as unit dose strength 750 mg and will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gepotidacin
Description: Gepotidacin tablets will be available as unit dose strength 750 mg and will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gepotidacin
Description: Gepotidacin tablets will be available as unit dose strength 750 mg and will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gepotidacin
Description: Gepotidacin tablets will be available as unit dose strength 750 mg and will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gepotidacin
Description: Gepotidacin tablets will be available as unit dose strength 750 mg and will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cimetidine
Description: Cimetidine tablets will be available as unit dose strength 400 mg and will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Rifampicin Capsules will be available as unit dose strength 300 mg and will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam oral syrup 2 milligrams per milliliter (mg/mL) will be available to be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam oral syrup 2 milligrams per milliliter (mg/mL) will be available to be administered orally.
Study: NCT01972438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Control Intervention

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Control Intervention
Study: NCT04493931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Digoxin tablets will be available as unit dose strength 0.25 mg and will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Digoxin tablets will be available as unit dose strength 0.25 mg and will be administered orally.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching to gepotidacin
Description: Placebo matching to gepotidacin tablets will be administered orally.
Study: NCT01114204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: IV Ferumoxytol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Sucrose
Description: IV Iron Sucrose
Study: NCT01391520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: deferiprone
Description: 3 tablets (treatment arm assigned in double-blind, randomized manner) will be given every 12 hours for a total of 8 days, beginning 1-3 hours prior to angiography

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 tablets (treatment arm assigned in double-blind, randomized manner) will be given every 12 hours for a total of 8 days, beginning 1-3 hours prior to angiography
Study: NCT02138630

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Capsaicin

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar capsule
Study: NCT01261702

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: magnesium sulphate
Description: The magnesium group (Group M, n=16) received 50 mg/kg of magnesium sulphate infusion in 10 minutes before induction and then 15 mg/kg/hr until the end of the surgery.
Study: NCT01090570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX3397
Description: Once-daily oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX3397
Description: Once-daily oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX3397
Description: Once-daily oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX3397
Description: Once-daily oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX3397
Description: Once-daily oral capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLX3397
Description: Once-daily oral capsules
Study: NCT01543243

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stochastic resonance whole-body vibration A
Description: Immediate effects (one minute after intervention): over 5 sets with 6 Hz, Noise 4 and than 1 Hz, Noise 1.~Long term effect: over four weeks, three times a week with 6 Hz, Noise 4 and than over four weeks three times a week with 1 Hz, Noise 1.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stochastic resonance whole-body vibration A
Description: Immediate effects (one minute after intervention): over 5 sets with 6 Hz, Noise 4 and than 1 Hz, Noise 1.~Long term effect: over four weeks, three times a week with 6 Hz, Noise 4 and than over four weeks three times a week with 1 Hz, Noise 1.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stochastic resonance whole-body vibration B
Description: Immediate effects (one minute after intervention): over 5 sets with 1 Hz, Noise 1 and than 6 Hz, Noise 4.~Long term effect: over four weeks, three times a week with 1 Hz, Noise 1 and than four weeks three times a week with 6 Hz, Noise 4.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stochastic resonance whole-body vibration B
Description: Immediate effects (one minute after intervention): over 5 sets with 1 Hz, Noise 1 and than 6 Hz, Noise 4.~Long term effect: over four weeks, three times a week with 1 Hz, Noise 1 and than four weeks three times a week with 6 Hz, Noise 4.
Study: NCT02238379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 24 International Units of Oxytocin in a Nasal Spray

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will contain all ingredients except the active oxytocin in the Nasal Spray.
Study: NCT00604526

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High dose rate (HDR) brachytherapy using Iridium 192 radioactive seeds
Description: Pre-tx Sexual function questionnaire Quality of Life baseline, Treatment with HDR (Two days) Treatment: Iridium 192 radioactive seeds temporarily inserted into patient. Post treatment (after HDR) Month 1 (+/- 2 weeks), 3 (+/- 1 month), 6 (+/- 1 month), 9 (+/-1 month), 12 (+/- 1 month)\* NCI CTC GU and GI assessment,IPSS, IIEF, PSA lab test, Prostate HRQOL~\*After 1 year, will follow up with doctor about every 6 months.
Study: NCT01040858

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Strategy Training
Description: Cognitive Strategy Training will consist of weekly 120-minute group sessions for 10 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparison group
Description: Participants in the experimental group will receive the Cognitive strategy intervention during the first ten weeks of their participation in the study, whereas comparison group participants will continue to receive usual care (no cognitive strategy intervention) during their participation in the study (but will be offered cognitive strategy intervention after the end of the study).
Study: NCT02157779

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Intervention
Description: Includes individual therapy sessions using cognitive and behavioral strategies addressing problems with anger intensity / frequency / management
Study: NCT00836381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolterodine extended-release (ER) 4mg
Description: Tolterodine extended-release (ER) 4mg once daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical Placebo once daily
Study: NCT03425396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omadacycline tablets
Description: Oral Omadacycline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omadacycline tablets
Description: Oral Omadacycline
Study: NCT02157779

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Intervention
Description: Includes individual therapy sessions using supportive and problem-solving strategies.
Study: NCT03211364

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glenohumeral mobilization
Description: Comparing the effect of angular mobilization in frontal or scapular plane and of providing soft tissue techniques on hemiplegic shoulder range of motion and pain.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glenohumeral mobilization
Description: Comparing the effect of angular mobilization in frontal or scapular plane and of providing soft tissue techniques on hemiplegic shoulder range of motion and pain.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Scapular mobilization
Study: NCT03222193

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRP
Description: 3 months of TRP tongue retraining
Study: NCT00778583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin 100 mg capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrofurantoin 100 mg capsules
Study: NCT04111003

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: local anesthesia
Description: administering local anesthesia in the region of the planned restorative procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: local anesthesia
Description: administering local anesthesia in the region of the planned restorative procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth restored using SFRC filling
Description: Restoration of an endodontivally treated molar using a shor-fiber base filling and veneering composite
Study: NCT03425396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omadacycline tablets
Description: Oral Omadacycline
Study: NCT04111003

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tooth restored using Ceramic indirect endocrown
Description: Restoration of an endodontically treated molar using a ceramic indirect restoration
Study: NCT04051164

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation Technique
Description: PMRT begins by assuming a comfortable position of lying down, sitting or leaning back.~Patient is asked to take a breathe in and intentionally contract muscle and hold muscle and after that release all tension and focus on sensation of relaxation. Each muscle group is tensed for 5-7 seconds and relaxed for 20-30 seconds. PMRT is given twice a day for one week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Strengthening exercises of residual limb: After amputation strengthening exercises of residual limb is necessary to prevent shortening of muscles and tightening of joints, moreover it is necessary to make residual limb strong and flexible in order to use a prosthesis. This include Hip abduction, prone hip extension and Prone position. Gait training: This include standing exercises in the parallel bars with or without the prosthesis. Initial walking exercises in which the patient is taught to raise each knee alternately and to try to take weight on his limb as much as possible. Deep Breathing exercise: Deep breathing 10-15 repetitions twice a day.
Study: NCT03546894

Intervention type: DRUG
Intervention: Brigatinib
Description: Brigatinib tablets.

Intervention type: DRUG
Intervention: Alectinib
Description: Alectinib capsules.

Intervention type: DRUG
Intervention: Ceritinib
Description: Ceritinib capsules.

Intervention type: DRUG
Intervention: Lorlatinib
Description: Lorlatinib capsules.

Intervention type: DRUG
Intervention: Any FDA Approved ALK Inhibitors
Description: FDA approved ALK inhibitors available for treatment.
Study: NCT01162681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A-623
Description: High dose given subcutaneously once a week for up to 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A-623
Description: Low dose given subcutaneously once a week for up to 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A-623
Description: High dose given subcutaneously once every 4 weeks for up to 52 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo comparator is a matched volume given subcutaneously once a week or once every 4 weeks for up to 52 weeks
Study: NCT01588626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6140
Description: tablet
Study: NCT03425396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omadacycline tablets
Description: Oral Omadacycline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrofurantoin capsules
Description: Oral Nitrofurantoin
Study: NCT01663090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol